WeVote
Log In

Bill

Bill

S 4504

Requires health insurance carriers to provide opportunity to clinical laboratory and laboratory services provider to participate as preferred or contracting provider in carriers' provider network.

2026-2027 Regular Session Introduced by Vin Gopal

Health insurers must offer clinical labs a pathway to become preferred or contracting providers, expanding lab network participation.

Introduced in the Senate, Referred to Senate Commerce Committee
0
WeVote Research Nonpartisan
Bill Summary · S 4504

Summary of Bill S 4504 (Session 222, New Jersey)

Purpose and intent

  • The bill requires health insurance carriers operating in New Jersey to provide clinical laboratories and laboratory services providers with the opportunity to participate as preferred or contracting providers within the carriers’ provider networks.
  • The overarching goal is to enhance access to laboratory services, promote fair contracting opportunities for laboratory providers, and potentially improve reimbursement practices and network adequacy for lab services.

Key provisions and changes

  • Provider participation opportunity: Health insurance carriers must offer clinical laboratories and laboratory services providers a pathway to become preferred or contracting providers within the insurer’s network. This codifies a formal option for labs to participate in network arrangements.
  • Network designation: Carriers would need to designate certain laboratories as preferred or contracting providers, presumably subject to standard contracting processes (rates, terms, and credentialing), ensuring labs have a clear route to network participation.
  • Non-discrimination in access: The bill seeks to ensure that laboratory providers are not arbitrarily excluded from contracting opportunities and that they have a fair chance to negotiate terms with carriers.
  • Transparency and terms: While the text available here does not spell out all specifics, such bills typically require clarity around credentialing criteria, performance expectations, credentialing timelines, and the financial terms of contracts (reimbursement rates, coding and billing standards, and dispute resolution).
  • Scope of laboratories: The provision generally covers clinical laboratories and laboratory services providers (which may include independent reference laboratories, hospital-based labs, and other lab service entities involved in collection, testing, and reporting of laboratory results).

Who would be affected

  • Health insurance carriers/insurers: Must establish a process to consider and contract with laboratory providers as preferred or contracted network providers.
  • Clinical laboratories and laboratory services providers: Gains a defined opportunity to participate in insurer networks as preferred/contracting providers, potentially expanding access to a larger patient population and shaping reimbursement dynamics.
  • Patients/consumers: Could benefit from broader access to in-network laboratory services, potentially shorter wait times and more predictable costs when using contracted labs.
  • Healthcare providers and facilities: May experience changes in referral patterns and collaboration with labs that become preferred providers within insurer networks.

Procedural and timeline aspects

  • The bill establishes new requirements for health insurance carriers but does not specify exact implementation timelines in the summary text available. Typically, once enacted, carriers would be given a reasonable period to modify contracting processes, credentialing procedures, and network directories to incorporate the new preferred/contracting provider pathway for laboratories.
  • Enforcement and oversight: The bill would likely be administered by the New Jersey Department of Banking and Insurance or relevant oversight bodies, with potential rules or regulations to operationalize the statutory requirement and address disputes or non-compliance.

Additional context

  • Sponsor: Co-sponsor Vin Gopal.
  • The summary does not include detailed definitions or all regulatory specifics (e.g., credentialing standards, dispute resolution mechanisms, or specific reimbursement benchmarks). If enacted, subsequent regulations or amendments would clarify these elements.

If you’d like, I can tailor this summary to focus on particular stakeholders (labs, insurers, patients) or add potential economic implications based on typical contract dynamics in insurer-lab arrangements.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.